Sculptra: Difference between revisions
No edit summary |
Citation bot (talk | contribs) Add: doi-access. | Use this bot. Report bugs. | Suggested by Headbomb | Linked from Wikipedia:WikiProject_Academic_Journals/Journals_cited_by_Wikipedia/Sandbox3 | #UCB_webform_linked 227/594 |
||
| (24 intermediate revisions by 20 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Cosmetic procedure}} |
|||
'''Sculptra''' |
'''Sculptra''' is a proprietary formulation of [[polylactic acid|poly-<small>L</small>-lactic acid]] (PLLA) that is an [[Food and Drug Administration|FDA]]-approved [[dermal]] filler manufactured by Dermik Laboratories, which conducts the American business of Aventis Dermatology, the global dermatology unit of [[Aventis]] (of [[Sanofi-Aventis]]). |
||
PLLA was approved by the FDA on August 3, 2004, for the treatment of facial [[fat]] loss (also called facial [[lipoatrophy]]). According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically “for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with [[human immunodeficiency virus]] (HIV).<ref>{{cite web|last=US FDA|title=Sculptra Aesthetic Label| |
PLLA was approved by the FDA on August 3, 2004, for the treatment of facial [[fat]] loss (also called facial [[lipoatrophy]]). According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically “for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with [[human immunodeficiency virus]] (HIV).<ref>{{cite web|last=US FDA|title=Sculptra Aesthetic Label|website=www.accessdata.fda.gov |url=http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030050c.pdf}}</ref><ref>{{cite web|last=US FDA|title=Medical Device User Fee and Modernization Act (MDUFMA) 2005|website=[[Food and Drug Administration]] |url=https://www.fda.gov/ohrms/dockets/dockets/05n0364/05n-0364-tr00001.txt|accessdate=12 August 2013}}</ref> Facial lipoatrophy is a condition in which people lose fat in their faces, especially in their cheeks and around their eyes and temples. People with [[HIV]] who take anti-HIV drugs may develop lipoatrophy. Sculptra was subsequently approved by the FDA for use with non-HIV patients with wrinkles, despite substantial complications reported to the FDA.<ref>{{cite web|last=US FDA|title=Sculptra Aesthetic Modified Label|url=http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030050S002c.pdf|accessdate=12 August 2013}}</ref> |
||
* [[Lipodystrophy]] |
* [[Lipodystrophy]] |
||
After the injection, it will take around 1 to 1.5 months to grow natural collagen |
After the injection, it will take around 1 to 1.5 months to grow natural collagen. Bruising and swelling may occur post injection, which will go down within a week. After the injection, patients are directed to massage the treatment area in order to maintain smooth, level and evenly distributed results and prevent granuloma formation. |
||
== Sculptra used in Cosmetic Medicine == |
|||
Today, Sculptra is used "off label" for other aesthetic enhancements, such as a non-surgical butt lift, alongside a wide range of anatomical regions of the body for overall rejuvenatory effects.<ref>{{Cite journal |last=Christen |first=Marie-Odile |date=2022-06-21 |title=Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA) |journal=Clinical, Cosmetic and Investigational Dermatology |volume=15 |pages=997–1019 |doi=10.2147/CCID.S359813 |issn=1178-7015 |pmc=9233565 |pmid=35761856 |doi-access=free }}</ref> |
|||
== References == |
== References == |
||
{{reflist}} |
{{reflist}} |
||
[[Category:Cosmetics chemicals]] |
[[Category:Cosmetics chemicals]] |
||
Latest revision as of 08:49, 4 September 2023
Sculptra is a proprietary formulation of poly-L-lactic acid (PLLA) that is an FDA-approved dermal filler manufactured by Dermik Laboratories, which conducts the American business of Aventis Dermatology, the global dermatology unit of Aventis (of Sanofi-Aventis).
PLLA was approved by the FDA on August 3, 2004, for the treatment of facial fat loss (also called facial lipoatrophy). According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically “for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV).[1][2] Facial lipoatrophy is a condition in which people lose fat in their faces, especially in their cheeks and around their eyes and temples. People with HIV who take anti-HIV drugs may develop lipoatrophy. Sculptra was subsequently approved by the FDA for use with non-HIV patients with wrinkles, despite substantial complications reported to the FDA.[3]
After the injection, it will take around 1 to 1.5 months to grow natural collagen. Bruising and swelling may occur post injection, which will go down within a week. After the injection, patients are directed to massage the treatment area in order to maintain smooth, level and evenly distributed results and prevent granuloma formation.
Sculptra used in Cosmetic Medicine
[edit]Today, Sculptra is used "off label" for other aesthetic enhancements, such as a non-surgical butt lift, alongside a wide range of anatomical regions of the body for overall rejuvenatory effects.[4]
References
[edit]- ^ US FDA. "Sculptra Aesthetic Label" (PDF). www.accessdata.fda.gov.
- ^ US FDA. "Medical Device User Fee and Modernization Act (MDUFMA) 2005". Food and Drug Administration. Retrieved 12 August 2013.
- ^ US FDA. "Sculptra Aesthetic Modified Label" (PDF). Retrieved 12 August 2013.
- ^ Christen, Marie-Odile (2022-06-21). "Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA)". Clinical, Cosmetic and Investigational Dermatology. 15: 997–1019. doi:10.2147/CCID.S359813. ISSN 1178-7015. PMC 9233565. PMID 35761856.